Evidence map›Paper›PMID 27149857›Full record

ArticleBMC medical imaging2016

Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers.

Luca Pio Stoppino, Nicola Della Valle, Stefania Rizzi, Elsa Cleopazzo, Annarita Centola, Donatello Iamele, Christos Bristogiannis, Giuseppe Stoppino, Roberta Vinci, Luca Macarini

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC medical imaging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 45 citations in OpenAlex.

  1. Trial
  2. Observational
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Inflammatory bowel disease cross-sectional imaging: What's new?United European gastroenterology journal · 2022
    Review
  9. Saudi Arabia consensus guidance for the diagnosis and management of adults with inflammatory bowel disease.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2022
    Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Luca Pio StoppinoDivision of Diagnostic Imaging, Department of Surgical Sciences, University of Foggia, Viale Luigi Pinto n.1, Foggia, 71122, Italy. luca.stoppino@unifg.it.
Nicola Della ValleDivision of Gastroenterology, Department of Surgical Sciences, University of Foggia, Viale Luigi Pinto n.1, Foggia, 71122, Italy.
Stefania RizziDivision of Diagnostic Imaging, Department of Surgical Sciences, University of Foggia, Viale Luigi Pinto n.1, Foggia, 71122, Italy.
Elsa CleopazzoDivision of Diagnostic Imaging, Department of Surgical Sciences, University of Foggia, Viale Luigi Pinto n.1, Foggia, 71122, Italy.
Annarita CentolaDivision of Diagnostic Imaging, Department of Surgical Sciences, University of Foggia, Viale Luigi Pinto n.1, Foggia, 71122, Italy.
Donatello IameleDivision of Diagnostic Imaging, Department of Surgical Sciences, University of Foggia, Viale Luigi Pinto n.1, Foggia, 71122, Italy.
Christos BristogiannisDivision of Diagnostic Imaging, Department of Surgical Sciences, University of Foggia, Viale Luigi Pinto n.1, Foggia, 71122, Italy.
Giuseppe StoppinoDivision of Gastroenterology, Department of Surgical Sciences, Azienda Sanitaria Locale Provincia di Foggia, Piazza della Libertà n.1, Foggia, 71122, Italy.
Roberta VinciDivision of Diagnostic Imaging, Department of Surgical Sciences, University of Foggia, Viale Luigi Pinto n.1, Foggia, 71122, Italy.
Luca MacariniDivision of Diagnostic Imaging, Department of Surgical Sciences, University of Foggia, Viale Luigi Pinto n.1, Foggia, 71122, Italy.
University of Foggia · ITASL Roma · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn recent years, the use of MRI in patients with Crohn's disease (CD) has increased. However, few data are available on how MRI parameters of active disease change during treatment with anti-TNF and whether these changes correspond to symptoms, serum biomarkers, or endoscopic appearance. The aim of this study was to determine the changes over time in MRI parameters during treatment with anti-TNF in patients with CD, and to verify the correlation between MRI score, endoscopic appearance and clinical-biological markers.

methodsWe performed a prospective single centre study of 27 patients with active CD (18 males and 9 females; median age of 27,4 ys; age range, 19-49). All patients underwent ileocolonoscopy and MRI at baseline and 26 weeks after anti-TNF therapy. Endoscopic severity was graded according to the Simple Endoscopic Score for Crohn's Disease (SES-CD) and Magnetic Resonance Index of Activity (MaRIA) was calculated. Patients underwent clinical evaluation (CDAI) and the C-reactive protein (CRP) level was measured. The associations between variables were assessed with Pearson's bivariate correlation analysis.

resultsA total of 135 intestinal segments were studied. The median patient age was 27,4 years, 67 % were male and the mean disease duration was 6,1 years. For induction of remission, 18 patients were treated with infliximab and 9 with adalimumab. The mean SES-CD and MaRIA scores significantly changed at week 26 (SES-CD: 14,7 ± 8,9 at baseline vs. 4,4 ± 4,6 at 26 weeks - p < 0.001; MaRIA: 41,1 ± 14,8 at baseline vs. 32,8 ± 11,7 at 26 weeks - p < 0.001). Also the CDAI and serum levels of CRP decreased significantly following treatment (p < 0.001). The overall MaRIA correlated with endoscopic score and with clinical activity (CDAI) both at baseline and at week 26 (p < 0.05). The correlation between overall MaRIA and CRP was significant only at week 26 (p < 0.001).

conclusionsThe MaRIA has a good correlation with SES-CD, a high accuracy for prediction of endoscopic mucosal healing and is a reliable indicator to monitor the use of TNF antagonists in patients with CD.

Indexed as

AdalimumabAdultColonoscopyC-Reactive ProteinCrohn DiseaseFemaleHumansInfliximabMagnetic Resonance ImagingMaleMiddle AgedProspective StudiesSeverity of Illness IndexTreatment OutcomeYoung AdultAdalimumabC-Reactive ProteinInfliximabAnti-TNF drugsCrohn’s diseaseMagnetic resonance enterographySimple Endoscopic Score for Crohn’s Disease

Identifiers

PMID27149857
PMCPMC4857261
OpenAlexW2345573097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.